Integrating Anatomical, Molecular and Clinical Risk Factors in Gastrointestinal Stromal Tumor of the Stomach

BACKGROUND: Adjuvant imatinib for 3 years is recommended to patients with high-risk gastrointestinal stromal tumor (GIST). Risk stratification is inaccurate, and risk assessments are further complicated by the increased use of neoadjuvant treatment. Anatomical criteria for prognostication have not b...

Descripción completa

Detalles Bibliográficos
Autores principales: Hølmebakk, Toto, Wiedswang, Anne Marit, Meza-Zepeda, Leonardo A., Hompland, Ivar, Lobmaier, Ingvild V. K., Berner, Jeanne-Marie, Stoldt, Stephan, Boye, Kjetil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Sarcoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460510/
https://www.ncbi.nlm.nih.gov/pubmed/33651216
http://dx.doi.org/10.1245/s10434-021-09605-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460510/
https://www.ncbi.nlm.nih.gov/pubmed/33651216
http://dx.doi.org/10.1245/s10434-021-09605-8

Ejemplares similares